Dehydroglyasperin D
Catalog No: CFN96516
Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29 human colorectal cancer cells through direct interaction with phosphatidylinositol 3-kinase; it also mediates suppression of both COX-2 expression and the MLK3 signalling pathway through direct binding and inhibition of MLK3. Dehydroglyasperin D shows strong ferric reducing activities and effectively scavenged DPPH, ABTS(+), and singlet oxygen radicals.
Dehydroleucodine
Catalog No: CFN96587
Dehydroleucodine has antidiarrheal, anti-inflammatory, anti-microbial, embryotoxicity, gastric cytoprotective, anti-cancer activities. Dehydroleucodine has an important inhibitory effect in cellular pathways regulating adipocyte differentiation by modulating the PPARγ expression, which is known to play a pivotal role during adipogenesis. Dehydroleucodine may be attributed to interference with multiple targets on the level of transcription factors, such as NF-kappaB, and cytokines. Dehydroleucodine induces a TP73-dependent transcriptional regulation of multiple cell death target genes in human glioblastoma cells.
Dehydrovomifoliol
Catalog No: CFN89279
Dehydrovomifoliol could be a marker of Polish heather honey. Dehydrovomifoliol exhibits moderate acetylcholinesterase (AChE) inhibitory activities. Dehydrovomifoliol shows significant cytotoxic activities against three human cancer cell lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, and the IC(50) values in the range 3.7-8.1 microM.
